Tenecteplase Dosing for High-Risk Pulmonary Embolism
For an adult with acute high-risk (massive) pulmonary embolism without contraindications, administer tenecteplase as a single weight-based intravenous bolus over 5 seconds using the standard STEMI dosing regimen: 30 mg for patients <60 kg, 35 mg for 60-69 kg, 40 mg for 70-79 kg, 45 mg for 80-89 kg, and 50 mg for patients ≥90 kg. 1
Weight-Based Dosing Protocol
The weight-adjusted regimen is derived from myocardial infarction trials but has been adopted for pulmonary embolism based on tenecteplase's pharmacokinetic properties 1, 2:
- <60 kg: 30 mg IV bolus 1
- 60-69 kg: 35 mg IV bolus 1
- 70-79 kg: 40 mg IV bolus 1
- 80-89 kg: 45 mg IV bolus 1
- ≥90 kg: 50 mg IV bolus 1
The dose is administered as a single bolus over 5 seconds, which represents a major practical advantage over alteplase's 2-hour infusion 1, 2. This single-bolus administration is possible because tenecteplase has a 6-fold longer half-life (22 minutes) compared to alteplase (3.5 minutes) 2.
Administration Protocol
- Give tenecteplase before or concurrent with anticoagulation (unfractionated heparin or LMWH) 1
- Administer via peripheral intravenous catheter 3
- Do not delay administration while awaiting imaging confirmation if the patient is in hemodynamic collapse or cardiac arrest is imminent 1
Expected Hemodynamic Response
Anticipate rapid clinical improvement 1:
- 30-35% reduction in pulmonary perfusion defect at 24 hours 1
- 92% of patients show clinical and echocardiographic improvement within 36 hours 1
Bleeding Risk and Monitoring
The major safety concern is hemorrhage, particularly in the first 36-48 hours 4:
- Major bleeding rate: approximately 13% 1
- Intracranial hemorrhage: 1.8-2% 1
- Symptomatic ICH typically occurs within the first 36 hours 4
- Monitor patients throughout the entire hospital stay (up to 8 days) because delayed hemorrhagic complications can still arise 4
Absolute Contraindications
Do not administer tenecteplase if any of the following are present 1:
- Prior intracranial hemorrhage
- Known structural cerebral vascular lesion
- Known malignant intracranial neoplasm
- Recent significant head trauma or intracranial/intraspinal surgery
- Recent stroke (within 3 months for ischemic stroke)
- Active bleeding or bleeding diathesis
Special Population: Elderly Patients
Patients >75 years have significantly higher bleeding risk, particularly intracranial hemorrhage, and may require dose reduction 1. One case report describes successful use of reduced-dose tenecteplase (0.37 mg/kg or 17.5 mg) in a patient over 90 years old with high-risk PE, though this approach lacks robust evidence 5.
Critical Pitfalls to Avoid
Do not use tenecteplase routinely in intermediate-risk PE without careful risk-benefit assessment, given the 2% stroke risk 1. The indication is specifically for high-risk (massive) PE with hemodynamic instability, hypotension, shock, or need for vasopressor support 1.
Do not delay administration in massive PE with hemodynamic collapse while awaiting imaging—clinical diagnosis may be sufficient when cardiac arrest is imminent 1.
Do not re-administer tenecteplase if re-occlusion occurs, as this may lead to excessive bleeding complications 1.
Alternative Thrombolytic Option
If tenecteplase is unavailable, alteplase 100 mg over 2 hours is an acceptable alternative for massive PE 3, 1. The FDA recommends withholding anticoagulation during the 2-hour alteplase infusion period 3.